Skip to main content

Table 1 Registered COVID-19 Therapeutics and Vaccine Trials in Sub-Saharan Africa as of November 5, 2020

From: COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa

Country Title Interventions Sponsor/Collaborators Phase Enrolment target Enrolling Children < 18 years Start date
Ghana PROTECT-Surg
Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19
Drug: Hydroxychloroquine
Drug: Lopinavir/Ritonavir
Drug: Hydroxychloroquine + Lopinavir/Ritonavir
Drug: standard of care
National Institute of Health Research, UK |
University for Development Studies School of Medicine and Health Sciences Tamale Teaching Hospital
Phase 3 6400 Yes (≥16 years) 25-Apr-20
South Africa
A study to determine if a new COVID-19 vaccine safely generates protective immune responses in adults in Kenya Single dose of ChAdOx1 nCoV-19 vaccine vs Verorab (rabies vaccine) University of Oxford
KEMRI Wellcome Trust Program
University of the Witwatersrand, Johannesburg
Phase 1/2 400 in Kenya
2000 (1950 HIV-uninfected and 50 people living with HIV) in South Africa
No 28-Oct-20 in Kenya
24-Jun-20 in South Africa
Nigeria LACCTT
Lagos COVID-19 Chloroquine Treatment Trial
Drug: Chloroquine phosphate
Drug: Hydroxychloroquine sulphate
Lagos State Government
Nigerian Institute of Medical Research
Not Applicable 600 No 17-Apr-20
Coronavirus Response - Active Support for Hospitalised COVID-19 Patients
Drug: Aspirin
Drug: Losartan
Drug: Simvastatin
London School of Hygiene and Tropical Medicine Phase 3 1000 No 01-Apr-20
IHP Detox tea trial
Efficacy and safety of IHP Detox Tea for treatment of Corona virus disease 2019: a pilot placebo-controlled randomized trial
IHP Detox Tea (a special blend of Andrographis paniculata, Garcinia kola and Psidium guajava) Neimeth International Pharmaceuticals Plc Not Applicable 72 No 01-May-20
Does ivermectin cure and/or prevent COVID-19?
Drug: ivermectin 6 mg
Drug: ivermectin 12 mg
Drug: placebo
Rachel Eye Center, Lagos University Teaching Hospital Phase 3 45 Yes (stated as ‘all ages’) 23-Apr-20
Senegal SEN-CoV-Fadj
Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal
Drug: Hydroxychloroquine
Drug: Hydroxychloroquine + Azithromycin
Institut Pasteur de Dakar
Fann Hospital, Senegal
Ministry of Health, Senegal
Diamniadio Children Hospital, Senegal
Dalal Jamm Hospital, Senegal
Epicentre, Paris, France
Phase 3 258 Yes (≥15 years if married; ≥18 years if not married) 01-Jun-20
Hydroxychloroquine, Azithromycin and Zinc for the treatment of SARS-CoV-2 infection in Senegal
Drug: Hydrochloroquine 600 mg plus Azythromycin
Drug: Hydrochloroquine 400 mg plus Azythromycin
Drug: Zinc
Faculty of Medicine University Cheikh Anta Diop of Dakar Senegal. Phase 3 384 No 01-Jun-20
South Africa CQOTE
Chloroquine Outpatient Treatment Evaluation for HIV-COVID-19
Drug: Chloroquine or hydroxychloroquine University of Cape Town Phase 3 560 No 01-May-20
BCG Vaccination for Healthcare Workers in COVID-19 Pandemic Biological: Bacille Calmette-Guerin (BCG)
Other: Placebo Comparator
TASK Applied Science
(University of Cape Town)
Phase 3 500 No 04-May-20
Sudan GA & COVID19
Potential Role of Gum Arabic as Immunomodulatory Agent Among COVID 19 Patients
Dietary Supplement: Acacia Senegal
Dietary Supplement: Pectin
Al-Neelain University
University of Khartoum
Phase 2
Phase 3
110 Yes (≥5 to 90 years) 01-Jun-20
South Africa
Public health emergency SOLIDARITY trial of treatments for COVID-19 infection in hospitalized patients
1. Local standard of care alone
OR local standard of care plus one of
2. Remdesivir
3. Chloroquine or hydroxychloroquine
4. Lopinavir + ritonavir
5. Lopinavir + ritonavir plus interferon-beta
World Health Organization Phase 3 10,000 No 01-Mar-20
South Africa
CROWN CORONATION: Chloroquine RepurpOsing to healthWorkers for Novel CORONAvirus mitigaTION Drug: Low-dose chloroquine/hydroxychloroquine
Drug: Mid dose chloroquine or hydroxychloroquine
Drug: High dose chloroquine or hydroxychloroquine
Drug: Placebo
Washington University School of Medicine/Bill and Melinda Gates Foundation Phase 3 55,000 No 01-Apr-20
Madagascar Efficacy of New COVID 19 Treatment Efficacy of Artesunate IV alone or combined with vitamin C IV for the treatment of COVID-19 Ministry of Health, Madagascar Phase 2   No 29-Apr-20
South Africa ENSEMBLE
Ad26.COV2.S1 for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants
Biological: Ad26.COV2.S1
Other: Placebo
Janssen Pharmaceutical Companies
University of the Witwatersrand, Johannesburg
Phase 1/2 6000 from Argentina, Brazil, Chile, Columbia, Mexico, Peru, Philippines, USA, Ukraine and South Africa No 2-Nov-20
South Africa Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals Biological: BNT162b1
Biological: BNT162b2
Other: Placebo
Pfizer and Biontech Phase 2/3 11,000 from U.S., Argentina and Brazil, Germany, Turkey and South Africa No No date
South Africa Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant NVX-CoV2373 Novavax
Coalition for Epidemic Preparedness Innovations
University of the Witwatersrand, Johannesburg
Phase 2 2904 (2650 HIV-uninfected and 240 people living with HIV) No 17-Aug-20
  1. Search strategy: The following clinical trials registers were searched:,, the Pan African Clinical Trial Registry (PACTR) and WHO international clinical trials registry platform (ICTRP). The following search terms were used: “COVID” (subject field) AND “interventional” OR “Randomized” (study type). Studies conducted in all 55 African Union member states are listed after cross checking for duplicates across registries. Multi-centric trials are listed as one entry